About the ‘Do You C Us?’ campaign
Pfizer and Cancer52 are jointly embarking on a campaign to raise public awareness of the challenges facing people with rare and less common cancers in England. Despite the name, rare and less common cancers account for nearly half of new cancer diagnoses and over half of cancer-related deaths.
The impact of COVID-19 means that some cancer centres paused their services, moved consultations to video or online, or offered different treatments. The overall number of people going to their GP with symptoms fell and in turn led to fewer diagnoses. This means it is more important than ever to raise awareness of rare and less common cancers, so people seek medical advice for any concerning symptoms.1
This new initiative aims to unite Pfizer, Cancer52 and its member charities to raise awareness of rare and less common cancers and highlight the need for people to come forward and let GPs know of any concerns.
Dr Ellie Cannon
When we talk about ‘rare and less common cancers’ we actually mean all cancers beyond the four most cancers which are breast, prostate, lung and bowel. What is surprising for many people is that ‘rare and less common cancers’ actually account for nearly half of all new cancer diagnoses and over half of cancer-related deaths. So many are in fact not that rare at all.
It is always true with cancer that early diagnosis is key. Rare and less common cancers can present themselves in a variety of ways. Symptoms are often vague such as back pain, fatigue, weight-loss or nausea. Any new or unusual changes to your body should prompt a discussion with your doctor particularly if they are prolonged. More often than not, symptoms are not anything sinister, but if it is cancer, the chances of effective treatment are always higher when they are detected early.
‘Do You C Us?’ aims to raise awareness of the unique challenges faced by those living with rare and less common cancers and amplify their voice – we need to ensure all cancers are ‘seen’ as early as possible.
COVID and its effect on health services has impacted this visibility between patients and their healthcare professionals: we know people have held back from speaking to a GP or attending scans, not wanting to come forward about seemingly trivial symptoms like those often experienced with rare and less common cancers. This needs to change. We all need to work to ensure we are more aware and empowered to diagnose all cancers as early as possible.
Cancer52 – Jane Lyons, CEO
Our united vision is to see a better future for everyone affected by rare and less common cancers.
We need to work together to promote improved diagnosis, treatment and support. The ‘Do You C Us?’ campaign is an important way of bringing people together to improve awareness and understanding of the challenges faced.
Cancer52 represents nearly 100 predominantly small patient support group cancer charities united by their vision of seeing a better future for everyone affected by the rare and less common cancers, which account for more than half of all cancer deaths in the UK.
Its aim is to promote improved diagnosis, treatment and support for those affected by rare and less common cancers. Cancer52 works on matters that impact on the rare and less common cancer community – defined as all cancers outside the ‘big four’ of breast, prostate, lung and bowel.